리제네론 파마슈티컬스, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionFamily Management Corp
Latest Disclosed Ownership3,794 shares
Latest Disclosed Value $ 2,931,396
Family Management Corp ownership in REGN / Regeneron Pharmaceuticals, Inc.

On May 15, 2026 - Family Management Corp filed a 13F-HR form disclosing ownership of 3,794 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $2,931,396 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 935 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 305.78% during the quarter.

Family Management Corp has a history of taking positions in derivatives of the underlying security (REGN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:REGN / Regeneron Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,794 2,859 305.78 2,931 306.52 0.3515
2026-02-17 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 935 -52 -5.27 722 30.14 0.0912
2025-11-13 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 987 -3,079 -75.73 555 -74.04 0.0763
2025-08-14 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,066 -138 -3.28 2,135 -19.95 0.3193
2025-05-15 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,204 80 1.94 2,666 -9.23 0.4357
2025-02-14 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,124 124 3.10 2,938 -30.14 0.4719
2024-11-14 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,000 -2,650 -39.85 4,205 -39.85 0.6942
2024-08-14 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,650 374 5.96 6,989 15.71 1.2278
2024-05-15 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,276 577 10.12 6,041 20.68 1.1119
2024-02-14 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,699 -443 -7.21 5,005 -0.97 1.0390
2023-11-14 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,142 -63 -1.02 5,055 13.37 1.1479
2023-08-14 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,205 -86 -1.37 4,459 -13.76 0.9761
2023-05-15 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,291 320 5.36 5,169 19.99 1.1900
2023-02-14 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,971 -65 -1.08 4,308 3.61 1.0500
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,036 -66 -1.08 4,158 15.28 1.0697
2022-08-15 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,102 -269 -4.22 3,607 -18.94 0.9711
2022-05-16 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,371 -13 -0.20 4,450 10.37 1.2334
2022-02-14 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,384 119 1.90 4,032 6.36 1.0475
2021-11-15 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,265 61 0.98 3,791 9.41 1.0461
2021-08-13 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,204 -882 -12.45 3,465 3.34 0.9173
2021-05-14 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,086 63 0.90 3,353 -1.18 1.0535
2021-02-10 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,023 1,796 34.36 3,393 15.96 1.1626
2020-11-13 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 5,227 -1,457 -21.80 2,926 -29.80 1.2836
2020-08-13 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 6,684 -1,920 -22.32 4,168 -0.79 1.6963
2020-05-06 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,604 -112 -1.28 4,201 28.35 2.0986
2020-02-11 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,716 -14 -0.16 3,273 35.14 1.1292
2019-11-15 2019-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 8,730 -7 -0.08 2,422 -11.44 0.9024
2019-11-12 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 8,669 -68 2,405 1,006,183.5312
2019-08-14 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 8,737 134 1.56 2,735 -22.59 1.0734
2019-05-14 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,603 4,087 90.50 3,533 109.43 1.5232
2019-02-14 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,516 4,516 1,687 0.7068
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-11-15 2021-09-30 13F REGENERON PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-08-13 2021-06-30 13F REGENERON PHARMACEUTICALS COM Call 200 112 n/a n/a n/a
2020-05-06 2020-03-31 13F REGENERON PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-11 2019-12-31 13F REGENERON PHARMACEUTICALS COM Call 600 -66.67 225 -54.91 n/a n/a n/a
2019-11-15 2019-09-30 13F/A REGENERON PHARMACEUTICALS COM Call 1,800 0.00 499 -11.37 n/a n/a n/a
2019-11-12 2019-09-30 13F REGENERON PHARMACEUTICALS COM Call 1,800 499 n/a n/a n/a
2019-08-14 2019-06-30 13F REGENERON PHARMACEUTICALS COM Call 1,800 563 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.